Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial

1. Thiery-Vuillemin, A.
2. de Bono, J.
3. Hussain, M.
4. Roubaud, G.
5. Procopio, G.
6. Shore, N.
7. Fizazi, K.
8. dos Anjos, G.
9. Gravis, G.
10. Joung, J.Y.
11. Matsubara, N.
12. Castellano, D.
13. Degboe, A.
14. Gresty, C.
15. Kang, J.
16. Allen, A.
17. Poehlein, C.
18. Saad, F.